AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 152 min read$CDNA

Hanna John Walter JR sold $528K of CDNA

Hanna John Walter JR (President and CEO) sold 21,998 shares of CareDx, Inc. (CDNA) at $24.02 ($0.53M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 15, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$528.4K is newly disclosed, but the presence of a pre-arranged 10b5-1 plan suggests reduced informational content.

02

Market read

This is a modest sentiment datapoint; it is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the signal is typically weak.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-15; sale executed 2026-06-11.

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO Hanna John Walter Jr sold 21,998 shares on 2026-06-11 for ~$528.4K under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and provides no new operating/regulatory catalyst.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

  • issuer
    CareDx, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • insider
    Hanna John Walter Jr

    President and CEO; sold 21,998 shares on 2026-06-11 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CDNA insider trading history →

Related articles

SEP 25
$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).

finance.yahoo.com2 min